Lonza, a CDMO for the biopharma industry, has announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies. Following product approval, the agreement will make use of a significant proportion of the capacity at the CDMO’s large-scale facility under construction in Visp, which will accommodate six 20,000 L bioreactors. Approximately 75% of the facility’s available capacity is now reserved.
The announcement develops of an existing customer relationship under which the CDMO provides highly potent payload, drug-linker and conjugation services. The large-scale supply of monoclonal antibodies is aimed to further simplify the supply chain.
Jean-Christophe Hyvert, President, Biologics and Cell & Gene Divisions, Lonza, commented: “This expanded customer relationship truly exemplifies our value and capabilities as a strategic partner on the path to commercialisation. We can offer an integrated and simplified supply chain, which provides security of supply and delivers economies of scale. We are proud to expand our partnership to deliver the commercial supply of this important class of molecule at our Ibex biopark, which will help treat patients suffering from cancer.”
Charles Christy, Director, Commercial Solutions, Lonza, added: “This deal reinforces the speed and flexibility of the Ibex Solutions concept. Having supported the development of the customer’s ADC from clinical trials towards commercial approval, we are pleased to continue to support our customer as this latest key molecule moves towards commercial manufacture. This growing partnership is built on trust, service, delivery and supply chain simplification, with all the critical elements for our customer’s ADC manufactured at a single site.”
